Gynecologic Cancers

The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab (Avastin), according to an announcement by Mylan during its fourth quarter 2019 earnings call.

The FDA has accepted a supplemental New Drug Application (sNDA) for niraparib (Zejula) for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.

Study findings, “changed how we see and treat patients with ovarian cancer,” said one expert.

The FDA has granted a priority review for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.

An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.

Gynecologic cancers present some of the most dangerous cancer-related threats to women, here's how to help patients understand what to look out for and the realities of their treatment.

New real-world data shows that PARP inhibitors have the potential to help patients with ovarian cancer and could be an affordable option for them.

The FDA approves the use of niraparib in the treatment of patients with HRD-positive advanced ovarian cancer based on results from the phase II QUADRA study.

Advanced ovarian cancer is deadly for female patients with the disease, but results from a new study show promise for a new frontline treatment.

At the 2019 European Society for Medical Oncology, new study results showed promise for a frontline combination therapy for patients with newly diagnosed, advanced ovarian cancer.

A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.

The FDA has granted accelerated approval to the combination of lenvatinib and pembrolizumab in the treatment of patients with advanced endometrial carcinoma.

Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.

Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.

While the US Preventative Services Task Force expanded their recommendations of who should be tested for BRCA mutations, there are still issues left unaddressed, according to one expert.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.

Molecular testing has led to monumental strides in the field of ovarian cancer, offering women with the disease more personalized treatment options.

Some patients with advanced ovarian cancer may be better candidates for primary debulking surgery, while others should start chemotherapy.

The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for niraparib (Zejula) for the treatment of patients with advanced ovarian cancer.

Studies have shown that heated chemotherapy may benefit women with ovarian cancer, but is this the right treatment for everyone? One expert weighs in.

The use of oral contraceptives not only decreases a woman’s risk of developing ovarian cancer, but can also decrease the risk of dying from the disease, too, according to recent research.

Health care providers need to break the cycle of inappropriate symptom communication to help improve patients’ quality of life.

Chemotherapy-induced periphreal neuropathy can affect patients' daily living, and some individuals may be more prone to it than others.

Creating a way to analyze the postings of patients and caregivers seeking peer support can give doctors and researchers insights about how to help them.

Oncology nurses must discuss treatment options and adverse events with their patients who have ovarian cancer.

Sexual health is an important issue that nurses should discuss with their patients.

Here are the top 5 Oncology Nursing News stories for February 2019.

There are some adverse events that are common to all PARP inhibitors, and others that are specific to each drug.